LUMOS PHARMA, INC.
DelistedCIK 1126234fmd_1NNQP97YVHHYAF9QE61Q8PSB9TManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2000 to Sep 30, 2024, 67 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 173 | 69 | 36 | 29 | 12 | 0 | 0 | 0 | 2 | 2 |
| Research and development | 36 | 71 | 93 | 70 | 46 | 6 | 9 | 16 | 18 | 22 |
| Total operating expenses | 55 | 102 | 127 | 102 | 75 | 10 | 26 | 32 | 34 | 39 |
| Operating income | 118 | (34) | (91) | (73) | (62) | (10) | (26) | (31) | (32) | (37) |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 1 | 2 |
| Other non-operating income (expense) | 0 | (0) | 0 | 0 | 2 | 0 | 7 | 0 | 1 | 3 |
| Income before taxes | 118 | (34) | (91) | (73) | (61) | (10) | (20) | (31) | (31) | (34) |
| Income tax expense | 22 | 7 | (5) | (1) | (7) | 0 | (14) | (1) | (0) | (0) |
| Net income from continuing operations | 96 | (40) | (85) | (72) | (54) | (10) | (6) | (30) | (31) | (34) |
| Net income | 96 | (40) | (85) | (72) | (54) | (10) | (6) | (30) | (31) | (34) |
| Net income to common shareholders | (9) | – | – | – | – | (13) | (6) | (30) | – | – |